CBD and full spectrum cannabis oil brand, Cannuba, is supporting the UK’s first national pilot study for medical cannabis, Project TWENTY21, which launched earlier this month.
Run by Drug Science, the UK’s leading independent scientific body on drugs, Project TWENTY21 aims to enrol 20,000 patients into the pilot before the end of 2021, using a real word data patient registry to assess efficacy, safety, quality-adjusted life year (QALYs), and patient reported outcomes in those prescribed medical cannabis.
The pilot will investigate specific uses of medicinal cannabis, focusing on times in which alternative treatment has failed in:
- Chronic pain
- PTSD, with a focus on the veteran community
- Multiple sclerosis
- Tourette’s syndrome
- Prison populations as a harm reduction strategy
- Cannabis use disorder and substance use disorder as a harm reduction strategy.
Project TWENTY21 will develop a body of evidence using a real-world data registry. This data will then be used to support applications to health authorities in the expectation that there will soon be a new regulatory system for medical cannabis in the UK.
The pilot scheme is part of the ongoing work of the Drug Science Cannabis Working Group, which launched at the House of Lords earlier this year. The working group, which is looking to develop approaches to improving patient access to medical cannabis in the UK, includes Cannuba board members, as well as other leading drug science experts, patient representatives, policy makers and other industry partners.
Rob James, CEO of Cannuba Ltd, said: “The study will be a great opportunity to collate scientific, tangible statistics for medical cannabis. It’s exciting to be at the forefront of meaningful scientific research taking place in the UK.”